Osteoporosis Part 2: Treatment and Fracture Management

Section 1: Bisphosphonates — Mechanism, Administration, Adverse Effects, and the Drug Holiday

Bottom line: bisphosphonates bind hydroxyapatite, are taken up by osteoclasts during resorption, and inhibit the mevalonate pathway to disrupt osteoclast cytoskeletal organization and induce apoptosis; oral alendronate, risedronate, and ibandronate plus intravenous (IV) zoledronic acid are the standard agents; oral dosing requires plain water on an empty stomach with the patient remaining upright for 30 minutes (60 minutes for oral ibandronate); the major adverse effects are esophagitis, atypical femur fractures (subtrochanteric/diaphyseal transverse fractures with prodromal thigh pain after ≥5 years of therapy), and rare osteonecrosis of the jaw (ONJ); a drug holiday is recommended after 5 years of oral therapy or 3 years of IV therapy.

Bisphosphonates are the first-line pharmacologic treatment for osteoporosis. They are synthetic analogs of pyrophosphate that bind avidly to hydroxyapatite, the mineral component of bone. Once bound to the bone surface, bisphosphonates are taken up by osteoclasts during resorption. Inside the osteoclast, nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting cytoskeletal organization, blocking formation of the ruffled border required for resorption, and inducing osteoclast apoptosis. The net effect is potent reduction in bone resorption, shifting the remodeling balance toward formation and increasing BMD over time.

Oral bisphosphonates: alendronate 70 mg once weekly (treatment) or 35 mg weekly (prevention); risedronate 35 mg weekly or 150 mg monthly; ibandronate 150 mg monthly orally or 3 mg quarterly IV (with weaker evidence for hip-fracture reduction). Intravenous zoledronic acid is dosed at 5 mg IV once yearly, is the most potent bisphosphonate, and offers perfect adherence because it is given by infusion.

The administration requirements for oral bisphosphonates are tested directly. Bioavailability is poor (only 1–3% absorbed). To maximize absorption and minimize esophageal injury, the medication must be taken first thing in the morning on an empty stomach, swallowed with a full glass of plain water (not coffee, juice, or mineral water), and the patient must remain upright (sitting or standing) for at least 30 minutes. No food, drink, or other medications are permitted during that window. The window is agent-specific and the exception is testable: alendronate and immediate-release risedronate require 30 minutes, oral ibandronate requires 60 minutes, and delayed-release risedronate is the odd one out, taken immediately after breakfast with 30 minutes upright afterward rather than fasting beforehand. Calcium supplements bind bisphosphonates and must be separated from the dose.

Bisphosphonates reduce vertebral fractures by 40–70% and hip fractures by 40–50%; non-vertebral fractures are also reduced. The benefit begins within the first year.

A critical pharmacologic distinction: bisphosphonates are anti-resorptive (they slow resorption rather than build new bone). The BMD increase reflects filling-in of remodeling spaces and continued secondary mineralization. This contrasts with anabolic agents (teriparatide, romosozumab) that directly stimulate osteoblast activity and new bone formation.

Renal contraindications are testable. Bisphosphonates are renally excreted and accumulate in severe renal impairment. They are contraindicated when the creatinine clearance (CrCl) is below 30–35 mL/min depending on agent — alendronate and zoledronic acid at 35, risedronate and ibandronate at 30. In a patient with chronic kidney disease (CKD) and osteoporosis, denosumab becomes the preferred anti-resorptive because it is not renally cleared. Since January 2024, however, denosumab carries an FDA boxed warning for severe hypocalcemia in advanced CKD (particularly dialysis and CKD-MBD), so that preference is not unconditional: in advanced disease it requires calcium monitoring, and mild-to-moderate impairment above the bisphosphonate floor does not by itself justify choosing denosumab.

The adverse effects are heavily tested. Upper gastrointestinal effects (esophagitis, esophageal erosions and ulcerations) are the most common adverse effects of oral bisphosphonates and are minimized by strict adherence to the upright-with-water protocol. Oral bisphosphonates are contraindicated in patients with esophageal disorders that delay emptying (achalasia, esophageal stricture) and in patients who cannot remain upright for the required post-dose window.

Osteonecrosis of the jaw (ONJ) is rare but serious. It presents as exposed, nonhealing bone in the oral cavity, typically after a dental extraction or invasive dental procedure. The risk is much higher with high-dose IV bisphosphonate use in cancer patients than with osteoporosis-dose therapy. Dental evaluation and completion of necessary invasive dental work are recommended before starting therapy.

Atypical femoral fractures are associated with prolonged bisphosphonate use, typically after 5 or more years. They occur in the subtrochanteric region or femoral shaft (not the typical intertrochanteric or femoral neck location of osteoporotic hip fractures). The fractures are transverse or short oblique, occur with minimal or no trauma, and are often preceded by prodromal thigh or groin pain for weeks to months. They may be bilateral; if one occurs, image the contralateral femur. The proposed mechanism is excessive suppression of bone remodeling, which prevents repair of microdamage and allows stress fractures to propagate. Atypical femoral fractures drive the drug-holiday recommendation.

The drug holiday is a critical board topic. Bisphosphonates bind tightly to bone and continue to exert anti-resorptive effects long after the medication is stopped. The general recommendation is a drug holiday after 5 years of oral bisphosphonate therapy or 3 years of IV zoledronic acid therapy. During the holiday, BMD and fracture risk are reassessed periodically; treatment is resumed if BMD declines significantly or a new fracture occurs. Holiday duration is typically 2–3 years regardless of route: the long-term bisphosphonate task force gives one holiday range rather than a longer intravenous-specific holiday. What is not route-indifferent is the interval at which the patient is rechecked during the holiday. That interval is agent-specific, because skeletal retention differs (zoledronate above alendronate above risedronate): the same task force flags risedronate for earlier reassessment on its shorter biologic half-life, and the 2024 United Kingdom guideline specifies fracture-risk reassessment at about 18 months after risedronate or ibandronate, 2 years after alendronate, and 3 years after zoledronic acid. Grade that ladder honestly: no trial has compared holiday lengths by agent, and the ordering is mechanistic reasoning rather than trial evidence (Adler 2016; Gregson 2025). The route enters at the other end of the decision. Patients still at high risk at the 5-year oral or 3-year intravenous reassessment (older age, low hip T-score, high fracture-risk score, prior major fracture, or a fracture sustained on therapy) are candidates for continued therapy out to 10 years oral or 6 years intravenous with periodic re-evaluation rather than a holiday at all.

An acute-phase reaction with flu-like symptoms (fever, myalgia, arthralgia) can occur within 24–72 hours of IV bisphosphonate infusion, particularly with the first dose of zoledronic acid. It occurs in roughly 30% of first-dose patients (about 32% after the first zoledronic acid infusion, falling to about 7% after the second annual dose and about 3% after the third) and typically resolves within 48–72 hours. Two cell populations appear in the mechanism and both answers can be keyed, so know the order: peripheral blood monocytes take up the nitrogen-containing bisphosphonate and accumulate the mevalonate-pathway intermediates isopentenyl pyrophosphate and dimethylallyl pyrophosphate behind the blocked farnesyl pyrophosphate synthase, and those accumulated metabolites then activate gamma-delta T cells, which are the effector population releasing the inflammatory cytokines (interleukin-6, tumor necrosis factor alpha) that produce the fever and myalgia. Pretreatment with acetaminophen reduces severity, and the incidence diminishes with subsequent infusions.

Hypocalcemia can follow bisphosphonate administration when vitamin D is deficient, because abrupt resorption suppression removes a calcium flux source. Vitamin D and calcium should be replete (25-OH-D >30 ng/mL) before initiating any anti-resorptive.

Source: Hellerhoff, “Femurfraktur unter Bisphosphonattherapie 57W - CT Topo Volumen Rendering postoperatives Roentgen - 001”, via Wikimedia Commons, CC BY-SA 4.0. https://commons.wikimedia.org/wiki/File:Femurfraktur_unter_Bisphosphonattherapie_57W_-_CT_Topo_Volumen_Rendering_postoperatives_Roentgen_-_001.jpg

Source: Mikael Häggström, MD, “X-ray of mildly compressed hip fracture, annotated”, via Wikimedia Commons, CC0 1.0 (Public Domain). https://commons.wikimedia.org/wiki/File:X-ray_of_mildly_compressed_hip_fracture,_annotated.jpg